Efg Asset Management (Americas) Corp. Biomarin Pharmaceutical Inc Transaction History

Efg Asset Management (Americas) Corp.

$508 Million
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$74.43 - $92.22 $818,060 - $1.01 Million	10,991 Added 55.47%	30,807 $2.54 Million
Q1 2024 Apr 22, 2024	SELL	$83.81 - $99.0 $621,199 - $733,788	-7,412 Reduced 27.22%	19,816 $1.73 Million
Q4 2023 Feb 01, 2024	BUY	$76.22 - $98.51 $32,927 - $42,556	432 Added 1.61%	27,228 $2.63 Million
Q3 2023 Nov 09, 2023	BUY	$85.07 - $94.48 $867,203 - $963,129	10,194 Added 61.4%	26,796 $2.37 Million
Q2 2023 Aug 29, 2023	BUY	$86.68 - $100.3 $1.44 Million - $1.67 Million	16,602 New	16,602 $1.44 Million
Q1 2021 Apr 09, 2021	SELL	$74.73 - $90.69 $222,396 - $269,893	-2,976 Closed	0 $0
Q4 2020 Feb 05, 2021	SELL	$72.61 - $90.2 $4,356 - $5,412	-60 Reduced 1.98%	2,976 $261,000
Q3 2020 Nov 06, 2020	SELL	$71.87 - $131.03 $2.56 Million - $4.66 Million	-35,567 Reduced 92.14%	3,036 $231,000
Q2 2020 Jul 30, 2020	SELL	$79.55 - $124.22 $824,694 - $1.29 Million	-10,367 Reduced 21.17%	38,603 $4.76 Million
Q1 2020 May 08, 2020	SELL	$71.37 - $96.85 $457,909 - $621,389	-6,416 Reduced 11.58%	48,970 $4.14 Million
Q4 2019 Jan 28, 2020	BUY	$64.27 - $86.37 $1.36 Million - $1.83 Million	21,222 Added 62.12%	55,386 $4.68 Million
Q3 2019 Nov 05, 2019	SELL	$67.4 - $85.11 $33,160 - $41,874	-492 Reduced 1.42%	34,164 $2.3 Million
Q2 2019 Jul 09, 2019	BUY	$80.35 - $93.9 $42,987 - $50,236	535 Added 1.57%	34,656 $2.97 Million
Q1 2019 Apr 05, 2019	SELL	$84.2 - $98.62 $452,743 - $530,279	-5,377 Reduced 13.61%	34,121 $3.03 Million
Q4 2018 Feb 06, 2019	BUY	$80.14 - $106.07 $322,082 - $426,295	4,019 Added 11.33%	39,498 $3.36 Million
Q3 2018 Oct 09, 2018	BUY	$93.92 - $105.72 $607,380 - $683,691	6,467 Added 22.29%	35,479 $3.44 Million
Q2 2018 Aug 07, 2018	BUY	$76.01 - $99.03 $1.32 Million - $1.72 Million	17,340 Added 148.56%	29,012 $2.73 Million
Q1 2018 May 07, 2018	BUY	$77.67 - $92.63 $97,087 - $115,787	1,250 Added 11.99%	11,672 $946,000
Q4 2017 Feb 07, 2018	BUY	$80.76 - $95.13 $247,852 - $291,953	3,069 Added 41.74%	10,422 $929,000
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $144,112 - $169,770	1,788 Added 32.13%	7,353 $684,000
Q2 2017 Aug 14, 2017	BUY	N/A	5,565	5,565 $505,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.52 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.28 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.26 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$926 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$699 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (Americas) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (Americas) Corp. with notifications on news.

Account